

## **Force of infection: A determinant of vaccine efficacy?**

David C. Kaslow, M.D.

PATH

dkaslow@path.org

### **Abstract**

Vaccine efficacy (VE) can vary in different settings. Of the many proposed setting-dependent determinants of VE, force of infection (FoI) stands out as one of the most direct, proximate, and actionable. As highlighted by the COVID-19 pandemic, modifying FoI through non-pharmaceutical interventions (NPIs) use can significantly contribute to controlling transmission and reducing disease incidence and severity absent highly effective pharmaceutical interventions, such as vaccines. Given that NPIs reduce the FoI, the question arises as to if and to what degree FoI, and by extension NPIs, can modify VE, and more practically, as vaccines become available for a pathogen, whether and which NPIs should continue to be used in conjunction with vaccines to optimize controlling transmission and reducing disease incidence and severity.

### **Introduction**

Lower apparent vaccine efficacy (VE) in low resource settings, when compared to VE observed in high resource settings, has been reported for several pathogens, most notably poliovirus, typhoid, and rotavirus.<sup>1-5</sup> Observed VE also varied when evaluating a malaria vaccine candidate in different parasite transmission settings.<sup>6-8</sup> Numerous economic, social, and biological factors

have been proposed to explain these setting-dependent variations in VE.<sup>3,9-11</sup> Many, if not most, of the proposed economic and social determinants of VE, such as, country income status, living conditions, access to healthcare, appear to act indirectly and non-specifically on VE; whereas many but not all biological factors, such as co-infections, malnutrition, and enteropathy, presumably act directly and proximally on VE. More practically, identification of direct and proximal determinants of setting-dependent VE that hold the promise of actionable intervention(s) seem a most urgent need in efforts to enhance and/or sustain VE.

The COVID-19 pandemic has highlighted the contribution of non-pharmaceutical interventions (NPIs) in controlling transmission and reducing disease incidence and severity,<sup>12</sup> particularly in the absence of highly effective pharmaceutical interventions, such as vaccines. NPIs also contribute to controlling other major human diseases, including use of condoms for HIV/AIDS<sup>13</sup>, bed nets for malaria<sup>14</sup>, and hand washing for diarrhea<sup>15</sup>. By reducing the number of (susceptible) individuals effectively contacted by each (infected) person, e.g., through physical barriers, distancing, and masking, NPIs reduce  $\lambda$ , the force of infection (FoI) (see **Box 1**, Glossary of Key Terms). As vaccines become available for a pathogen, the question arises as to if and which NPIs should continue to be used, if not prioritized.<sup>16</sup> This then begs the broader use-inspired scientific question, as raised previously:<sup>8</sup> after optimizing the vaccine immunogen, formulation, dose level, and regimen, what remaining determinants of vaccine efficacy (VE) are amenable to intervention? More specifically, given the role of NPIs in reducing the FoI, if and to what degree is FoI, and by extension NPIs, a determinant of VE?

**Interrogating the potential relationship of force of infection and setting-dependent vaccine efficacy**

A two-step approach was taken to interrogate the potential relationship between FoI and VE. The first explored three mathematical scenarios of VE as a function of various FoI settings. The second followed up on the decades old observations of lower apparent oral poliovirus vaccine (OPV)<sup>1</sup> and typhoid vaccine<sup>5</sup> VE in low resource settings when compared to high resource settings by assessing the correlation between the incidence of disease in the placebo population (as a surrogate of FoI in the study population) and the observed VE in different geographical settings. Recent Phase 3 studies of malaria and rotavirus vaccine candidates across a number of settings, including low and high resource settings,<sup>6,17</sup> provided data for assessing if and how FoI might be a determinant of VE.

Both the thought experiment of setting-dependent VE of a hypothetical vaccine and the retrospective analyses of rotavirus and malaria Phase 3 efficacy results make a multitude of assumptions that limit the robustness and soundness of any conclusions. For simplicity, factors previously shown or hypothesized to influence transmission, susceptibility, VE, and/or FoI, such as, country income status, age, underlying medical conditions, co-infections, access to healthcare, seasonality, NPI use, spreading events, and strain differences across different settings, were excluded from consideration in both the hypothetical VE or observed VE analyses.

Given these significant limitations in the analyses, the primary goal of the present study was not to provide a definitive answer to the questions of if and to what degree FoI determines VE in different settings. Rather the goal of these analyses was to continue to raise the awareness of the potential impact of FoI on VE,<sup>8,18</sup> and to prompt prospective studies designed to assess if and how NPIs might reduce FoI and enhance VE when vaccines are introduced and scaled up. Ultimately well-designed studies that directly evaluate the potential relationship of FoI and

setting-dependent VE will provide the evidence needed for well-informed policy recommendations on the continued use or not of NPIs during vaccine introduction and scale-up.

### **Three scenarios of the potential mathematical consequences of force of infection on setting-dependent vaccine efficacy**

The potential effects of FoI on the level of VE were explored in three mathematical scenarios: 1)  $VE_{\text{constant}}$ , where VE is independent of FoI; 2)  $VE_{\text{linear}}$ , where VE decreases linearly as a function of increasing FoI; and, 3)  $VE_{\text{natural log}}$ , where VE decreases logarithmically as FoI. As noted above, multiple simplifying assumptions were made when considering the mathematical consequences of FoI on VE, including homogeneity in the population with respect to a number of factors, including pathogen transmission, host susceptibility to infection and disease, FoI over time in a specific setting, and protective immunity as a result of vaccination across settings.

With these simplifying assumptions in mind, equations that define the three mathematical scenarios (see **Box 2**, Vaccine efficacy as a function of Force of infection) are shown graphically in **Fig. 1**, using the example of a hypothetical vaccine that has a maximum VE of 83% studied under conditions of FoI that vary across three orders of magnitude, from 0.03 to 3.50 infections/person-year. While other mathematical relationships between VE and FoI may be considered, these three equations seemed a reasonable starting point from which to interrogate observed data from Phase 3 VE studies conducted in multiple epidemiological settings.

### **Empiric evidence of force of infection on observed setting-dependent vaccine efficacy**

Results from recent placebo-controlled Phase 3 studies of vaccine candidates for two diverse pathogens, *Plasmodium falciparum* and rotavirus, provided a database to determine which, if any, of the three mathematical scenarios best explained any setting-dependent differences in VE. In addition to the assumptions mentioned above, several additional assumptions noted below facilitated the analyses of these multi-setting VE studies.

First and foremost, the analyses of both pathogens assumed that the intent-to-treat (ITT) incidence of the most sensitive definition of the mildest disease end point in the youngest age cohort in the placebo arm best served as an internal Phase 3 study surrogate of  $\lambda$ , the force of infection. The validity of this assumption relies upon several other assumptions, including the absence of any significant herd effect (see **Box 1**, Glossary of Key Terms) on the control from the vaccinated arm of the Phase 3 study. The rationale for making this herd effect assumption, typically also assumed for the control used in estimating VE in the context of Phase 3 efficacy studies, relies upon: 1) the relatively small proportion of the total population in the study setting enrolled in the vaccinated group in the Phase 3 study; and, 2) the timing of incident disease in the control group relative to eliciting herd immunity and reaching the herd immunity threshold (see **Box 1**, Glossary of Key Terms) in the study population.

A third key assumption relied upon a comparison of trendlines from the three mathematical scenarios described above to the closest fit trendline of observed VE ( $VE_{\text{observed}}$ ) as a function of observed setting FoI ( $FoI_{\text{observed}}$ , incidence in the placebo group) to determine if and how VE varied as a function of FoI. In this regard, because the Phase 3 VE results for both pathogens were known a priori to vary by epidemiologic setting, the posterior probability was low of selecting the  $VE_{\text{constant}}$  mathematical scenario to categorize  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$ . As noted below for each specific analysis, the observed trendline may not necessarily reflect a

statistically significant association between  $VE_{\text{observed}}$  and  $FoI_{\text{observed}}$ , as assessed by a regression analysis.

### **Malaria parasite vaccine efficacy and force of infection**

A single pivotal Phase 3 VE study (NCT00866619) enrolled 15,459 participants in two age categories (young children aged 5–17 months and infants aged 6–12 weeks at the time of enrollment) across 11 clinical research sites in seven African countries (one site in Burkina Faso, Gabon, Malawi, and Mozambique; two sites in Ghana and Tanzania; and three sites in Kenya). The trial assessed, as a primary aim, VE of a three-dose regimen of RTS,S/AS01<sub>E</sub> against clinical malaria over 12 months follow-up.<sup>7</sup> In the per-protocol population of the 5–17 months age category,  $VE_{\text{observed}}$  was 51.3% (95% CI: 47.5 - 54.9; p-value <.0001) with a  $VE_{\text{observed}}$  range from 83.0% (95% CI: 37.2 - 95.4; p-value 0.0079) in a low parasite transmission site (Kilifi, Kenya) to 44.0% (95% CI: 36.8 - 50.3; p-value <.0001) in a high parasite transmission site (Nanoro, Burkina Faso) (see Annex 6 table 23, Ref 19). As noted above, the intent-to-treat (ITT) incidence of the more sensitive secondary definition of clinical malaria in the control group of infants aged 6–12 weeks at the time of enrollment (see Annex 7 table 177, Ref 20) served as the internal Phase 3 study  $FoI_{\text{observed}}$ , the surrogate of  $\lambda$  in the analyses.

The best fit trendline analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  revealed a logarithmic relationship (**Fig. 2**, Observed VE) with an  $R^2$  of 0.807. Regression analysis of  $VE_{\text{observed}}$  as a function of  $\ln FoI_{\text{observed}}$  revealed a Significance F of 0.006. Using the  $VE_{\text{natural log}}$  equation (**Box 2**), the observed  $VE_{\text{max}}$ ,  $VE_{\text{min}}$ ,  $FoI_{\text{max}}$ ,  $FoI_{\text{min}}$  and the  $FoI_{\text{observed}}$  from each site generated a

logarithmic relationship between the calculated site-specific VE and  $FoI_{\text{observed}}$  (**Fig 2**, Calculated VE). These analyses suggest that FoI functions as a determinant of RTS,S/AS01<sub>E</sub> VE.

### **Rotavirus vaccine efficacy and force of infection**

Multiple Phase 3 studies of two rotavirus vaccines, RV1 (Rotarix®) and RV5 (RotaTeq®), evaluated VE in diverse epidemiologic settings.<sup>17</sup> In comparison to the analyses conducted for malaria VE, the analyses of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  for rotavirus vaccines was complicated by the evaluation of two different vaccine candidates, with two different regimens, in several different clinical protocols. Some of the Phase 3 studies conducted in low resource settings did not collect data on the incidence of rotavirus gastroenteritis (RVGE) of any severity. The analyses excluded these studies due to the absence of an intent-to-treat incidence of any severity RVGE in the placebo group to serve as a surrogate of  $\lambda$ . The analyses also excluded data from countries in which the placebo group had no or just a single case of RVGE of any severity. From those studies that collected sufficient incidence of any severity RVGE in the placebo group, an Analysis of Variance failed to detect a statistically significant difference (p-value = 0.749) when categorizing  $FoI_{\text{observed}}$  by 2020 World Bank country income classifications (i.e., upper- v upper middle- v lower middle/lower-income country)<sup>21</sup> (**Table 1**).

For RV1, results from 10 countries in five independent Phase 3 studies<sup>17,22–26</sup> (see **Table 1**) met the above  $FoI_{\text{observed}}$  criteria for interrogation. The best fit trendline analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  revealed a linear relationship (**Fig. 3a** upper line, Observed VE) with an  $R^2$  of 0.3892 and regression analysis with a Significance F of 0.158. The  $VE_{\text{observed}}$  of 94.9% in one setting (Mexico) with  $FoI_{\text{observed}}$  of 13.79 appeared to be a significant outlier. Reanalysis absent the data from Mexico revealed a linear relationship (**Fig. 3a** middle line, Observed VE), with an  $R^2$  of 0.6264 and regression analysis Significance F of 0.0449. Using the  $VE_{\text{linear}}$  equation (**Box**

2), the observed  $VE_{\max}$ ,  $VE_{\min}$ ,  $FoI_{\max}$ ,  $FoI_{\min}$  and the  $FoI_{\text{observed}}$  from each of the 10 countries generated a linear relationship between the calculated site-specific VE and  $FoI_{\text{observed}}$  (**Fig. 3a** lower line, Calculated VE). These analyses suggest that FoI may function as a determinant of RV1 VE.

For RV5, results from 5 settings in three independent Phase 3 studies<sup>17,27–31</sup> (see **Table 1**) met the above  $FoI_{\text{observed}}$  criteria for interrogation. The best fit trendline analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  revealed an independent relationship (data not shown) with an  $R^2$  of -0.215 and regression analysis Significance F of 0.9838. Interrogating results from 7 settings in five independent Phase 3 studies<sup>17,27–32</sup> (see **Table 1**) by using the incidence of SRVGE in the placebo group as the  $FoI_{\text{observed}}$  and surrogate of  $\lambda$  in the analyses, the best fit trendline analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  revealed a linear relationship (**Fig 3B**, Observed VE) with an  $R^2$  of 0.6692 and regression analysis Significance F of 0.081. Using the  $VE_{\text{linear}}$  equation (**Box 2**), the observed  $VE_{\max}$ ,  $VE_{\min}$ ,  $FoI_{\max}$ ,  $FoI_{\min}$  and the  $FoI_{\text{observed}}$  from each of the 7 settings in the reanalysis generated a linear relationship between the calculated site-specific VE and  $FoI_{\text{observed}}$  (**Fig 3B** lower line, Calculated VE). These analyses suggest that FoI may function as a determinant of RV5 VE, when the  $FoI_{\text{observed}}$  in the analyses is the incidence of SRVGE in the placebo group.

## Conclusion

Of the many proposed determinants of setting-dependent VE, FoI provides one of the most direct, mechanistically proximate potential determinants. For many but not all pathogens, modifying the FoI provides one of the most actionable interventions to enhance or sustain VE.



While improving indirect or distal VE determinants, such as poverty, gut pathology, co-infections, and malnutrition, could significantly enhance efforts to control and eliminate simultaneously many pathogens, implementing interventions that effectively mitigate these VE determinants is complex and not immediately achievable. In contrast, modifying the FoI through the concomitant use of affordable, accessible, available, acceptable, and sustainable NPIs provides a proximate and actionable approach to optimizing VE. Considering and then prospectively verifying the speculation that introduction or continued optimal use of NPIs in an effort to reduce the FoI and thereby enhance or sustain VE, respectively, upon vaccine rollout seems prudent and, in the context of a pandemic, quite urgent.

## References

1. John, T. J. Immunisation Against Polioviruses in Developing Countries. *Rev. Med. Virol.* **3**, 149–160 (1993).
2. John, T. J. & Samuel, R. Herd immunity and herd effect: new insights and definitions. *Eur. J. Epidemiol.* **16**, 601–606 (2000).
3. Desselberger, U. Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors. *Pathogens* **6**, 65 (2017).
4. Lamberti, L. M., Ashraf, S., Walker, C. L. F. & Black, R. E. A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 Years. *Pediatr. Infect. Dis. J.* **35**, 992–998 (2016).
5. Simanjuntak, C. H. *et al.* Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. *Lancet Lond. Engl.* **338**, 1055–1059 (1991).
6. EMA. Mosquirix: Public Assessment Report. Mosquirix H-W-2300. [https://www.ema.europa.eu/en/documents/medicine-outside-eu/mosquirix-public-assessmentreport\\_en.pdf](https://www.ema.europa.eu/en/documents/medicine-outside-eu/mosquirix-public-assessmentreport_en.pdf) (2015).
7. Kaslow, D. C. & Biernaux, S. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap. *Vaccine* **33**, 7425–7432 (2015).
8. Kaslow, D. C. Certainty of success: three critical parameters in coronavirus vaccine development. *Npj Vaccines* **5**, 1–7 (2020).
9. Fischer Walker, C. L. & Black, R. E. Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. *BMC Public Health* **11**, S16 (2011).
10. Gruber, J. F. *et al.* Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries. *Pediatr. Infect. Dis. J.* **36**, 72–78 (2017).

11. Jiang, V., Jiang, B., Tate, J., Parashar, U. D. & Patel, M. M. Performance of rotavirus vaccines in developed and developing countries. *Hum. Vaccin.* **6**, 532–542 (2010).
12. Chu, D. K. *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* **395**, 1973–1987 (2020).
13. Weller, S. C. & Davis-Beaty, K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst. Rev.* (2002) doi:10.1002/14651858.CD003255.
14. Pryce, J., Richardson, M. & Lengeler, C. Insecticide-treated nets for preventing malaria. *Cochrane Database Syst. Rev.* **2018**, (2018).
15. Ejemot-Nwadiaro, R. I., Ehiri, J. E., Arikpo, D., Meremikwu, M. M. & Critchley, J. A. Hand-washing promotion for preventing diarrhoea. *Cochrane Database Syst. Rev.* (2020) doi:10.1002/14651858.CD004265.pub4.
16. Winskill, P., Walker, P. G., Griffin, J. T. & Ghani, A. C. Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. *BMJ Glob. Health* **2**, e000090 (2017).
17. Soares-Weiser, K., Bergman, H., Henschke, N., Pitan, F. & Cunliffe, N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. *Cochrane Database Syst. Rev.* (2019) doi:10.1002/14651858.CD008521.pub5.
18. Feikin, D. R., Scott, J. A. G. & Gessner, B. D. Use of vaccines as probes to define disease burden. *The Lancet* **383**, 1762–1770 (2014).
19. GSK. Annex 6 to the Clinical Study Report for Study 110021 (MALARIA-055 PRI). <https://s3.amazonaws.com/ctr-gsk-7381/110021/640ed3e6-81da-4067-90db->

bc8324f71a29/8946951f-0cfe-4ff7-b0e9-1103468776dc/gsk-110021-clinical-study-report-redact-01-v1-v3.pdf.

20. GSK. Annex 7 to the Clinical Study Report for Study 110021 (MALARIA-055 PRI).

[https://s3.amazonaws.com/ctr-gsk-7381/110021/9e419df1-fb51-4b82-8db2-](https://s3.amazonaws.com/ctr-gsk-7381/110021/9e419df1-fb51-4b82-8db2-4256fe3ae230/976c7711-02eb-405b-817f-859bcdb779e2/gsk-110021-clinical-study-report-redact-02-v1-v3.pdf)

[4256fe3ae230/976c7711-02eb-405b-817f-859bcdb779e2/gsk-110021-clinical-study-report-redact-02-v1-v3.pdf](https://s3.amazonaws.com/ctr-gsk-7381/110021/9e419df1-fb51-4b82-8db2-4256fe3ae230/976c7711-02eb-405b-817f-859bcdb779e2/gsk-110021-clinical-study-report-redact-02-v1-v3.pdf).

21. World Bank Country and Lending Groups – World Bank Data Help Desk.

<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>.

22. Vesikari, T. *et al.* Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. *The Lancet* **370**, 1757–1763 (2007).

23. Li, R. *et al.* Human rotavirus vaccine (RIX4414) efficacy in the first two years of life. *Hum. Vaccines Immunother.* **10**, 11–18 (2014).

24. Salinas, B. *et al.* Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414: A Randomized, Placebo-Controlled Trial in Latin American Infants. *Pediatr. Infect. Dis. J.* **24**, 807–816 (2005).

25. Kawamura, N. *et al.* Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. *Vaccine* **29**, 6335–6341 (2011).

26. Madhi, S. A. *et al.* Effect of human rotavirus vaccine on severe diarrhea in African infants. *N. Engl. J. Med.* **362**, 289–298 (2010).

27. Block, S. L. *et al.* Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life. *Pediatrics* **119**, 11–18 (2007).
28. Iwata, S. *et al.* Efficacy and safety of pentavalent rotavirus vaccine in Japan. *Hum. Vaccines Immunother.* **9**, 1626–1633 (2013).
29. Armah, G. E. *et al.* Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. *The Lancet* **376**, 606–614 (2010).
30. Vesikari, T. *et al.* Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine. *N. Engl. J. Med.* **354**, 23–33 (2006).
31. EMA. Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006. [https://www.ema.europa.eu/en/documents/variation-report/rotateq-h-c-669-p46-0045-epar-assessment-report\\_en.pdf](https://www.ema.europa.eu/en/documents/variation-report/rotateq-h-c-669-p46-0045-epar-assessment-report_en.pdf) (2006).
32. Zaman, K. *et al.* Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *Lancet Lond. Engl.* **376**, 615–623 (2010).
33. Vynnycky, E. & White, R. *An Introduction to Infectious Disease Modelling.* (OUP Oxford, 2010).
34. Orenstein, W. A. *et al.* Field evaluation of vaccine efficacy. *Bull. World Health Organ.* **63**, 1055–1068 (1985).
35. Vesikari, T. *et al.* Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. *Vaccine* **24**, 4821–4829 (2006).

36. GSK. Evaluate protective efficacy of diff strengths of human rotavirus vaccine after administration of 2 doses to infants aged 2 months: GSK 444563-006 Clinical Study Report. [https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=444563/006&attachmentIdentifier=ff878ec8-e42b-49cb-b9ef-6ea90ea32e86&fileName=gsk-444563-006-clinical-study-report-redact.pdf&versionIdentifier=\(2003\)](https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=444563/006&attachmentIdentifier=ff878ec8-e42b-49cb-b9ef-6ea90ea32e86&fileName=gsk-444563-006-clinical-study-report-redact.pdf&versionIdentifier=(2003)).
37. GSK. Vaccine Efficacy against Rotavirus Diarrhea; Vaccine Given with Routine Childhood Vaccinations in Healthy African Infants: GSK 102248 Clinical Study Report. [https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=102248&attachmentIdentifier=51cebf27-e59a-4c45-bed7-15429582d324&fileName=gsk-102248-clinical-study-report-redact.pdf&versionIdentifier=\(2009\)](https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=102248&attachmentIdentifier=51cebf27-e59a-4c45-bed7-15429582d324&fileName=gsk-102248-clinical-study-report-redact.pdf&versionIdentifier=(2009)).
38. GSK. Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants: GSK-113808-Clinical Study Report. [https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=113808&attachmentIdentifier=5056b56b-5311-466e-9f63-d1b647b37b89&fileName=gsk-113808-clinical-study-report-redact.pdf&versionIdentifier=\(2015\)](https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=113808&attachmentIdentifier=5056b56b-5311-466e-9f63-d1b647b37b89&fileName=gsk-113808-clinical-study-report-redact.pdf&versionIdentifier=(2015)).
39. GSK. To test 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines: GSK 102247/036 Clinical Study Report. <https://filehosting->

v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=102247/036&attachmentIdentifier=d31bed4a-8976-4b17-adf5-aba92145c9ca&fileName=gsk-102247-036-c-clinical-study-report-redact.pdf&versionIdentifier=(2006).

40. GSK. Efficacy, safety, reactogenicity & immunogenicity of the Rotarix vaccine in Japanese infants: GSK 107625 Clinical Study Report. <https://filehosting->

v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&parentIdentifier=107625&attachmentIdentifier=4b357e3f-f6a9-467a-ab54-0dc4f0a63da7&fileName=gsk-107625-clinical-study-report-redact.pdf&versionIdentifier=(2009).

## Text boxes

### Box 1. Glossary of key terms

**Force of infection:** Rate at which susceptible individuals in a population acquire an infectious disease in that population, per unit time. It is also known as the incidence rate or hazard rate.<sup>33</sup>

$$\text{Equation 1: } \lambda_t = \frac{c_e I_t}{N_t} \text{ (see equation 2.13, Ref 33)}$$

Where  $\lambda_t$  = force of infection at time t,  $c_e$  = number of individuals effectively contacted by each person per unit time,  $I_t$  = number of infected in the population at time t,  $N_t$  = number in the population at time t

**Efficacy:** The direct protection provided by vaccination against a defined clinical endpoint; it excludes any indirect (herd) effect.<sup>33</sup>

$$\text{Equation 2: } VE = \frac{ARU - ARV}{ARU} \times 100 = 1 - \frac{I_V / N_V}{I_U / N_U} \times 100 \text{ (see equations, Ref 34)}$$

Where VE = vaccine efficacy, ARU = attack rate in the unvaccinated population, ARV = attack rate in the vaccinated population,  $I_V$  = number of infected in the vaccinated population,  $N_V$  = number in the vaccinated population,  $I_U$  = number of infected in the unvaccinated population, and  $N_U$  = number in the unvaccinated population

**Herd immunity:** The proportion of a population immune to infection or disease.<sup>2,33</sup>

**Herd immunity threshold:** The proportion of the population required to be immune in the population for the infection incidence to reach steady state, i.e., the infection level is neither growing nor declining. To eliminate an infection in the population, the proportion of the population that is immune to infection must exceed this threshold value.<sup>33</sup>

**Herd effect:** The reduction in the rate of infection or disease in the unimmunized portion of a population as a result of immunizing a proportion of the population.<sup>2</sup> It is also known as indirect effect.



## Box 2. Vaccine efficacy as a function of Force of infection

The following equations define mathematical relationships between Vaccine Efficacy (VE) and Force of Infection (FOI) shown in Figure 1, when the relationship of VE is: 1) independent of FOI ( $VE_{\text{constant}}$ ); 2) linear to FOI ( $VE_{\text{linear}}$ ); or 3) logarithmic to FOI ( $VE_{\text{natural log}}$ ):

Equation 3:  $VE_{\text{constant}}$ : 
$$VE_S = - 0 * FOI_S + VE_{\text{max}}$$


Equation 4:  $VE_{\text{linear}}$ : 
$$VE_S = - \left( \frac{FOI_S - FOI_{\text{min}}}{FOI_{\text{max}} - FOI_{\text{min}}} \right) \times (VE_{\text{max}} - VE_{\text{min}}) + VE_{\text{max}}$$

Equation 5:  $VE_{\text{natural log}}$ : 
$$VE_S = - \left( \frac{\ln FOI_S - \ln FOI_{\text{min}}}{\ln FOI_{\text{max}} - \ln FOI_{\text{min}}} \right) \times (VE_{\text{max}} - VE_{\text{min}}) + VE_{\text{max}}$$

Where:  $VE_S$  is the VE in setting  $S$ ,  $VE_{\text{max}}$  is the highest observed VE, and  $VE_{\text{min}}$  is the lowest observed VE.


And, where  $FOI_S$  is the FOI in setting  $S$ ,  $FOI_{\text{min}}$  is lowest observed FOI, and  $FOI_{\text{max}}$  is the highest observed FOI.

**Fig 1. Vaccine Efficacy (VE) as a function of Force of Infection (FoI) for hypothetical vaccine**




Equations that define three mathematical scenarios (see **Box 2**, Vaccine efficacy as a function of force of infection) are shown graphically, using as an example a hypothetical vaccine with a maximum vaccine efficacy ( $VE_{max}$ ) of 83% and minimum VE ( $VE_{min}$ ) of 44.0% studied under conditions of force of infection (FoI) that vary across three orders of magnitude, from a minimum FoI ( $FoI_{min}$ ) 0.03 to a maximum FoI ( $FoI_{max}$ ) of 3.50 infections/person-year.

**Fig 2. Vaccine Efficacy (VE) as a function of Force of Infection (FoI) for malaria vaccine**



Best fit trendline analysis of observed vaccine efficacy ( $VE_{observed}$ ) as a function of observed force of infection ( $FoI_{observed}$ ) is shown as a logarithmic relationship (blue dotted line) with a  $R^2$  of 0.807. Significance F of 0.006 from a regression analysis of  $VE_{observed}$  as a function of  $\ln FoI_{observed}$  in the embedded table is shown. Using the  $VE_{natural\ log}$  equation (see **Box 2**, Vaccine efficacy as a function of force of infection), the observed  $VE_{max}$ ,  $VE_{min}$ ,  $FoI_{max}$ ,  $FoI_{min}$  and  $FoI_{observed}$  were used to calculate the  $VE_{natural\ log}$  in the embedded table and the calculated  $VE_{natural\ log}$  shown graphically (orange dotted line).

**Fig 3. Vaccine Efficacy (VE) as a function of Force of Infection (FoI) for rotavirus vaccines**



**a** RV1: Best fit trendline analysis of observed vaccine efficacy ( $VE_{\text{observed}}$ ) as a function of observed force of infection ( $FoI_{\text{observed}}$ ) is shown as a linear relationship for all 10 countries (blue dotted line) and for 9 countries (exclusion of the outlier, encircled blue dot; gray dotted line) with a  $R^2$  of 0.3892 and 0.6264, respectively. Significance Fs of 0.158 and 0.0449 from a regression analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  in the embedded table are shown. Using the  $VE_{\text{natural log}}$  equation (see **Box 2**, Vaccine efficacy as a function of force of infection), the observed  $VE_{\text{max}}$ ,  $VE_{\text{min}}$ ,  $FoI_{\text{max}}$ ,  $FoI_{\text{min}}$  and  $FoI_{\text{observed}}$  were used to calculate the  $VE_{\text{natural log}}$  in the embedded table and the calculated  $VE_{\text{natural log}}$  shown graphically (orange dotted line).

**b** RV5: Best fit trendline analysis of observed vaccine efficacy ( $VE_{\text{observed}}$ ) as a function of observed force of infection ( $FoI_{\text{observed}}$ ) is shown as a linear relationship (blue dotted line) with a

$R^2$  of 0.6692. Significance F of 0.081 from a regression analysis of  $VE_{\text{observed}}$  as a function of  $FoI_{\text{observed}}$  in the embedded table is shown. Using the  $VE_{\text{natural log}}$  equation (see **Box 2**, Vaccine efficacy as a function of force of infection), the observed  $VE_{\text{max}}$ ,  $VE_{\text{min}}$ ,  $FoI_{\text{max}}$ ,  $FoI_{\text{min}}$  and  $FoI_{\text{observed}}$  were used to calculate the  $VE_{\text{natural log}}$  in the embedded table and the calculated  $VE_{\text{natural log}}$  shown graphically (orange dotted line).

**Table 1.**

| <b>Country</b> | <b>Economy*</b> | <b>FOI<sub>observed</sub></b> | <b>(RV#)</b> | <b>NTC</b>    | <b>References</b> |
|----------------|-----------------|-------------------------------|--------------|---------------|-------------------|
| Finland        | H               | 16.3                          | RV5          | Not available | 35                |
| Brazil         | UM              | 16.1                          | RV1          | NCT00140673   | 24,36             |
| Malawi         | L               | 14.4                          | RV1          | NCT00241644   | 26,37             |
| Mexico         | UM              | 13.8                          | RV1          | NCT00140673   | 24,36             |
| South Africa   | UM              | 12.2                          | RV1          | NCT00241644   | 26,37             |
| EU/USA         | H               | 11.2                          | RV5          | NCT00092443   | 27                |
| China          | UM              | 10.6                          | RV1          | NCT01171963   | 23,38             |
| France         | H               | 10.0                          | RV1          | NCT00140686   | 22,39             |
| Japan          | H               | 10.0                          | RV1          | NCT00480324   | 25,40             |
| Finland        | H               | 8.8                           | RV1          | NCT00140686   | 22,39             |
| Japan          | H               | 7.1                           | RV5          | NCT00718237   | 28                |
| Ghana          | LM              | 7.1                           | RV5          | NCT00362648   | 29                |
| Venezuela      | UM              | 6.0                           | RV1          | NCT00140673   | 24,36             |
| China          | UM              | 5.4                           | RV5          | NCT02062385   | 31                |
| Czech Republic | H               | 4.1                           | RV1          | NCT00140686   | 22,39             |
| Kenya          | LM              | 3.7                           | RV5          | NCT00362648   | 29                |
| Bangladesh     | LM              | n/a                           | RV5          | NCT00362648   | 32                |
| Vietnam        | LM              | n/a                           | RV5          | NCT00362648   | 32                |

\* See Ref 21